GLP3-R + Cagrilintide is a compounded research-only blend combining retatrutide - Eli Lilly's investigational triple GLP-1/GIP/glucagon receptor agonist (LY3437943) - with cagrilintide, Novo Nordisk's long-acting amylin analog (AM833/NN0174-0833). The rationale parallels Novo Nordisk's CagriSema (cagrilintide plus semaglutide) but substitutes the more potent triple agonist. No clinical trial of this specific combination has been registered or completed; both components are themselves still investigational and not FDA-approved. Sold exclusively as a research chemical via compounding pharmacies and grey-market peptide vendors. All efficacy claims are extrapolated from the separate component trials.
—
best
price
—
per
mg
—
vendors
tracked
Research-only
stage
Formulation note
Retatrutide + Cagrilintide. Closest validated analog is CagriSema (cagrilintide + semaglutide, Novo Nordisk Phase III) — but distinct drug.
What's in this blend
Weight Loss
Retatrutide (LY3437943) is a once-weekly subcutaneous triple agonist of the GIP, GLP-1, and glucagon receptors developed by Eli Lilly.
Weight Loss
Cagrilintide (NN0174-0833, AM833) is a long-acting acylated amylin analog developed by Novo Nordisk for chronic weight management.
Vendor data
Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.
Browse all vendorsMechanism of action
The blend combines retatrutide, a unimolecular triple agonist at the GLP-1, GIP, and glucagon receptors (https://pubmed.ncbi.
Pharmacokinetic properties
Half-life
Retatrutide ~6 days; cagrilintide ~7-8 days subcutaneous (both support once-weekly dosing).
Routes
subcutaneous
Bioavailability
Both components are lipidated peptides; neither is orally bioavailable. Co-formulation is convenience-driven and does not change individual PK.
Amino-acid sequence
Use & research dosing
No clinical trial of this specific blend exists. Self-experimentation protocols typically maintain each component at its standard schedule: retatrutide 2-12 mg subcutaneous weekly, titrated up over many weeks, and cagrilintide 0.3-2.4 mg subcutaneous weekly, also titrated. Often combined into one weekly injection for convenience. Not FDA-approved; not in any registered trial. Stacking two potent appetite-suppressing mechanisms amplifies GI side-effect risk, so most protocols recommend titrating components individually first.
Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.
Rationale parallels CagriSema, substituting retatrutide for semaglutide. There is no published clinical evidence for this specific combination, so all efficacy expectations are extrapolated from the two individual phase 2/3 programs. Users should titrate each component individually before combining to manage tolerability. Stacking two heavily appetite-suppressing agents raises the risk of severe GI side effects and dehydration. Confidence in safety and efficacy of the blend specifically is low; cite component primaries rather than blend studies.
— SavePeptides editorial desk · last updated 2026-05-25
Cautions & contraindications
Research foundation
Facts verified
2026-05-25
Confidence
low
What this means
Vendor data coming soon
001 — Independent
SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.
002 — Vendor-funded
SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.
003 — Research use
SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.